Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00107432 · ClinicalTrials.gov registry record · Phase 2
Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
A Phase 2 study of Recurrent Malignant Mesothelioma and Epithelial Mesothelioma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 2
- Study locations
NCT00107432 is a Phase 2 study of Recurrent Malignant Mesothelioma and Epithelial Mesothelioma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 44 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT00107432, a Phase 2 study of Recurrent Malignant Mesothelioma and Epithelial Mesothelioma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial is studying how well sorafenib works in treating patients with malignant mesothelioma. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG sorafenib tosylate
Study Locations (2)
Illinois
- Cancer and Leukemia Group B - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2004-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00107432
The ClinicalTrials.gov registry entry for NCT00107432 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Recurrent Malignant Mesothelioma appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00107432 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00107432 about?
NCT00107432 is a clinical study titled "Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.". This phase II trial is studying how well sorafenib works in treating patients with malignant mesothelioma. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
What is the current status of trial NCT00107432?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2004-10.
What conditions does trial NCT00107432 study?
This clinical trial studies the following conditions: Recurrent Malignant Mesothelioma, Epithelial Mesothelioma, Sarcomatous Mesothelioma, Stage IA Malignant Mesothelioma, Stage IB Malignant Mesothelioma.
What interventions are being tested in trial NCT00107432?
The interventions under investigation include: laboratory biomarker analysis (OTHER), sorafenib tosylate (DRUG).
Who is sponsoring clinical trial NCT00107432?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00107432 being conducted?
This trial has 2 study locations across Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Malignant Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.